Promising Breakthrough with Muvalapline: Effective Treatment for High Lp(a) Levels and Reduced Complications

2023-09-02 12:15:27

A promising breakthrough in the treatment of high levels of Lp(a), a form of cholesterol that damages blood vessels, has been achieved with muvalapline. The results of the phase 1 trial of this investigational drug show a significant reduction in Lp(a) levels in patients, raising hopes of a decrease in complications.

You will also be interested

[EN VIDÉO] High cholesterol: 10 foods to avoid Cholesterol is a steroid lipid (fatty) present in the blood, necessary for the proper functioning…

There are two main carriers of cholesterol in the blood: high density lipoproteins (HDL), responsible for transporting it to the liver for elimination, and low density lipoproteins (LDL), responsible for distributing it to the cells of the body. LDL is often referred to as the “bad cholesterol” because of its association with an increased risk of cardiovascular events. To control these LDL levels, drugs – such as statins – have been developed, but their effectiveness varies between patients. In addition, there is a lipoprotein, lipoprotein (a) or Lp(a), which resembles LDL. It is even more detrimental to the walls of blood vessels and there is no treatment to reduce its level.

Muvalapline, a ray of hope in the treatment of Lp(a)

The synthesis of Lp(a) is mainly linked to genetic factors, which makes it particularly difficult to treat. For example, diets are not effective. However, recent research has brought out a molecule, muvalapline.

A phase 1 study, published in the Jama, involving 114 patients, was carried out to assess tolerance to this drug. The results showed that muvalapline could reduce Lp(a) levels significantly, up to 65%, when given at doses greater than 100 mg per day orally. In addition, no noticeable adverse reactions were observed during the short trial period (14 days).

Cholesterol from A to Z

Other clinical trials, phase 2 and phase 3 are still necessary before confirming or invalidating the interest of this molecule in the management of high Lp(a) levels. Nevertheless, these preliminary results mark a significant step towards better management of cardiovascular health.

1693657789
#cholesterol #management

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.